# A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

> **NCT00109707** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 507 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia
- Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
- Hypereosinophilic Syndrome
- Systemic Mastocytosis

## Interventions

- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT00109707
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 507 (ACTUAL)
- **Last updated:** 2021-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00109707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00109707, "A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00109707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*